C4 Therapeutics, Inc. Proceeds from Issuance of Convertible Preferred Stock
C4 Therapeutics, Inc. (CCCC) reported Proceeds from Issuance of Convertible Preferred Stock of $145.53 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-02-24.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2022-02-24
- C4 Therapeutics, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2020-12-31 was $0.00.
- C4 Therapeutics, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2020-09-30 was $4.50M.
- C4 Therapeutics, Inc. proceeds from issuance of convertible preferred stock for fiscal 2020 was $145.53M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $4.50M derived: sum of 2 quarters · filed 2022-02-24 | $145.53M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $145.53M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $141.03M 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |